Home » News » Press Releases 2009 » Positive outcome reached at 16 weeks for Avexa's ATC phase III trial
Positive outcome reached at 16 weeks for Avexa's ATC phase III trial
- Home
- News
- Corporate
- Investor Relations
- Presentations
- CEO's presentation to the 2009 AGM
- Chairman's address to the 2009 AGM
- Company Presentation April 2009
- HIV Glasgow Conference November 2008 Apricitabine Oral Presentation
- HIV Glasgow Conference November 2008 Apricitabine Poster
- ICAAC Poster Washington 2008
- AGM CEO Presentation November 2008
- Poster XV11 HIV Drug Resistance Workshop June 2008
- Investor Presentation March 2008
- BIO CEO Investor Conference New York February 2008
- CROI Poster Boston 2008
- CEO Presentation AGM 2007
- Investor Presentation October 2007
- Investor Roadshow Presentation 2007
- Investor Roadshow Presentation March 2007
- HIV Glasgow Conference November 2006 Apricitabine Poster
- AGM CEO presentation 2006
- Investor Roadshow Presentation November 2006
- FAQs
- Contact Us
Terms and Conditions |
Privacy Statement |
© 2008 Avexa Limited All Rights Reserved